Organization & Developments: Editas

Parents

Editas Medicine, Inc. (NASDAQ:EDIT)*

Children

@editasmed
*Has created a computer model that can identify the best genetic sequences to target a given gene.
2014: Gene Therapy's Next Generation
2016: Editas biotech stock drops by 26 percent over CRISPR patent dispute
2016: Editas Pursuing CRISPR: A Speculative Gem - Editas Medicine (NASDAQ:EDIT)
2016: Editas: A Win Big, Lose Big Gene Editing Play - Editas Medicine (NASDAQ:EDIT)
2016: Seattle-based Juno is paying $25 million upfront and another $22 million over five years to license Crispr to genetically engineer cells that can recognize and kill cancer cells.
2017: Editas Medicine: A Gene Editing Concern To Watch - Editas Medicine (NASDAQ:EDIT)
2017: Editas prevails in CRISPR/Cas9 patent dispute with UC; shares rally 28% - Editas Medicine (NASDAQ:EDIT)
2018: Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study
2018: Editas bags $25M from Allergan as FDA signs off on human CRISPR trial
2018: Editas gets approval for CRISPR study on patients with a rare disorder
2018: Editas sees three candidates in early-stage trials by 2022 - Editas Medicine (NASDAQ:EDIT)
2019: Better Buy: Editas Medicine vs. CRISPR Therapeutics
2019: Editas and BlueRock join forces
2019: Editas founder Katrine Bosley abruptly steps aside from the helm, just ahead of historic CRISPR move – Endpoints News
2019: Editas Medicine (EDIT) Investor Presentation - Slideshow_seekingalpha.com
2020: AbbVie cuts Editas CRISPR pact it inherited from Allergan
2020: Editas Medicine initiated with a Buy at SunTrust EDIT;ABBV
2020: Editas Medicine: Plagued By Uncertainty, Awed By The Potentia
2021: Editas Medicine: Editing The Way Toward A Potential 10 Bagger
2021: Editas: Data Was Eagerly Anticipated But Failed To Impress
2022: Editas Medicine: 3 Positives To Cling To In 2023 (And Why They May Not Be So Positive)_ seekingalpha.com
2022: Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch_ seekingalpha.com
2022: Editas shelves lead asset after proof-of-concept data whittles down likely patient population
2022: Editas' Latecomer SCD Therapy Shows Promise in Two Patients
2023: A Mispriced Contender In The Gene Editing Arena (NASDAQ:EDIT)
2023: After long-running patent battle, Vertex pays $100M to license Editas’ gene-editing tech
2023: ASH: After landmark FDA approvals, Editas still thinks its gene therapy differentiates itself enough from competition
2023: Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
2023: Editas Makes Good on Portfolio Reprioritization with Shoreline Deals
2023: Editas Medicine: Assessing The Impact Of Casgevy And Lyfgenia Approvals_ seekingalpha.com
2023: Editas Medicine: Pioneering Gene-Editing Solutions For Inherited Blood Disorders And Beyond_seekingalpha.com
2023: Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena
2023: Editas rewrites its own code after tough 2022, sending staff packing and editing down programs
2024: Could Editas Medicine Become the Next CRISPR Therapeutics?
2024: CRISPR Improves Vision in Clinical Trial
2024: Editas lays off 65% of staff, including CMO, after fruitless search for reni-cel partner
2024: Editas Medicine: A Risk/Reward Worth Considering
2024: Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch_seekingalpha.com
2024: Editas prioritizes in vivo gene therapies, looks to partner reni-cel
2024: Editas reviews path for gene editing therapy to save costs
2024: Editas spikes as Vertex Pharma deal boosts Q4 topline
2025: After strategic pivot, Editas lays out plan to target high cholesterol with gene editing
2025: Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
2026: Gene Editing Therapy Succeeds in 96% of Sickle Cell Disease Patients

Jumps

*Key People: Editas
Finance & Acquisitions: Editas

Made with TheBrain